Cardiac Myosin-Binding Protein C Is Required for Complete Relaxation in Intact Myocytes

The role of cardiac myosin-binding protein C (cMyBP-C) in cardiac contraction is still not fully resolved. Experimental ablation of cMyBP-C by various means resulted in inconsistent changes in Ca2+ sensitivity and increased velocity of force of skinned preparations. To evaluate how these effects are integrated in an intact, living myocyte context, we investigated consequences of cMyBP-C ablation in ventricular myocytes and left atria from cMyBP-C knock-out (KO) mice compared with wild-type (WT). At 6 weeks, KO myocytes exhibited mild hypertrophy that became more pronounced by 30 weeks. Isolated cells from KO exhibited markedly lower diastolic sarcomere length (SL) without change in diastolic Ca2+. The lower SL in KO was partly abolished by the actin-myosin ATPase inhibitors 2,3-butanedione monoxime or blebbistatin, indicating residual actin-myosin interaction in diastole. The relationship between cytosolic Ca2+ and SL showed that KO cells started to contract at lower Ca2+ without reaching a higher maximum, yielding a smaller area of the phase-plane diagram. Both sarcomere shortening and Ca2+ transient were prolonged in KO. Isolated KO left atria exhibited a marked increase in sensitivity to external Ca2+ and, in contrast to WT, continued to develop twitch force at low micromolar Ca2+. Taken together, the main consequence of cMyBP-C ablation was a defect in diastolic relaxation and a smaller dynamic range of cell shortening, both of which likely result from the increased myofilament Ca2+ sensitivity. Our findings indicate that cMyBP-C functions as a restraint on myosin-actin interaction at low Ca2+ and short SL to allow complete relaxation during diastole.

[1]  S. Nattel,et al.  Decreased phosphorylation levels of cardiac myosin-binding protein-C in human and experimental heart failure. , 2007, Journal of molecular and cellular cardiology.

[2]  Haitao Wen,et al.  Thin Filament Disinhibition by Restrictive Cardiomyopathy Mutant R193H Troponin I Induces Ca2+-Independent Mechanical Tone and Acute Myocyte Remodeling , 2007, Circulation research.

[3]  R. Moss,et al.  Radial displacement of myosin cross-bridges in mouse myocardium due to ablation of myosin binding protein-C. , 2007, Journal of molecular biology.

[4]  L. Carrier,et al.  Cardiac myosin-binding protein C in the heart. , 2007, Archives des maladies du coeur et des vaisseaux.

[5]  J. Seidman,et al.  Cardiac myosin binding protein c phosphorylation is cardioprotective , 2006, Proceedings of the National Academy of Sciences.

[6]  H. Granzier,et al.  New insights in the role of cardiac myosin binding protein C as a regulator of cardiac contractility. , 2006, Circulation research.

[7]  Ursula Ravens,et al.  Molecular Determinants of Altered Ca2+ Handling in Human Chronic Atrial Fibrillation , 2006, Circulation.

[8]  H. Reichenspurner,et al.  The MLCK‐mediated α1‐adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCɛ signaling , 2006 .

[9]  R. Moss,et al.  Ablation of myosin-binding protein-C accelerates force development in mouse myocardium. , 2006, Biophysical journal.

[10]  M. Gautel,et al.  Activation of Myocardial Contraction by the N-Terminal Domains of Myosin Binding Protein-C , 2006, Circulation research.

[11]  P. Tombe.  Myosin Binding Protein C in the Heart , 2006 .

[12]  R. Moss,et al.  Ablation of Cardiac Myosin-Binding Protein-C Accelerates Stretch Activation in Murine Skinned Myocardium , 2006, Circulation research.

[13]  G. Vassort,et al.  Length and protein kinase A modulations of myocytes in cardiac myosin binding protein C-deficient mice. , 2006, Cardiovascular research.

[14]  K. Lindenberg,et al.  Impairment of the ubiquitin-proteasome system by truncated cardiac myosin binding protein C mutants. , 2005, Cardiovascular research.

[15]  Daniel C. Lee,et al.  Myosin-Binding Protein C Phosphorylation, Myofibril Structure, and Contractile Function During Low-Flow Ischemia , 2005, Circulation.

[16]  J. Sellers,et al.  Mechanism of Blebbistatin Inhibition of Myosin II* , 2004, Journal of Biological Chemistry.

[17]  J. Ross,et al.  Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice. , 2004, Cardiovascular research.

[18]  J. Seidman,et al.  Reduced cross-bridge dependent stiffness of skinned myocardium from mice lacking cardiac myosin binding protein-C , 2004, Molecular and Cellular Biochemistry.

[19]  J. Seidman,et al.  Effect of Cardiac Myosin Binding Protein-C on Mechanoenergetics in Mouse Myocardium , 2004, Circulation research.

[20]  H. Watkins,et al.  Cardiac Myosin Binding Protein C: Its Role in Physiology and Disease , 2004, Circulation research.

[21]  D. Kass,et al.  Role of Cardiac Myosin Binding Protein C in Sustaining Left Ventricular Systolic Stiffening , 2004, Circulation research.

[22]  Y. Lecarpentier,et al.  Human homozygous R403W mutant cardiac myosin presents disproportionate enhancement of mechanical and enzymatic properties. , 2004, Journal of molecular and cellular cardiology.

[23]  L. Carrier,et al.  Effect of MyBP-C Binding to Actin on Contractility in Heart Muscle , 2003, The Journal of general physiology.

[24]  K. Schwartz,et al.  Biomolecular interactions between human recombinant beta-MyHC and cMyBP-Cs implicated in familial hypertrophic cardiomyopathy. , 2003, Cardiovascular research.

[25]  K. McDonald,et al.  Loaded Shortening, Power Output, and Rate of Force Redevelopment Are Increased With Knockout of Cardiac Myosin Binding Protein-C , 2003, Circulation research.

[26]  J. Ingwall,et al.  Decreased energetics in murine hearts bearing the R92Q mutation in cardiac troponin T. , 2003, The Journal of clinical investigation.

[27]  D. Gadsby,et al.  Paul F. Cranefield, M.D., Ph.D. April 28, 1925 to May 31, 2003 , 2003, The Journal of General Physiology.

[28]  A. Blamire,et al.  Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. , 2003, Journal of the American College of Cardiology.

[29]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[30]  K. McDonald,et al.  Hypertrophic Cardiomyopathy in Cardiac Myosin Binding Protein-C Knockout Mice , 2002, Circulation research.

[31]  M. Gautel,et al.  A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. , 2000, Circulation.

[32]  B. Hainque,et al.  COOH-terminal truncated cardiac myosin-binding protein C mutants resulting from familial hypertrophic cardiomyopathy mutations exhibit altered expression and/or incorporation in fetal rat cardiomyocytes. , 1999, Journal of molecular biology.

[33]  S. Winegrad.  Cardiac myosin binding protein C. , 1999, Circulation research.

[34]  R. Moss,et al.  Role of myosin heavy chain composition in kinetics of force development and relaxation in rat myocardium , 1998, The Journal of physiology.

[35]  Peter J Reiser,et al.  Electrophoretic separation and quantitation of cardiac myosin heavy chain isoforms in eight mammalian species. , 1998, American journal of physiology. Heart and circulatory physiology.

[36]  M. Gautel,et al.  Isoform transitions of the myosin binding protein C family in developing human and mouse muscles: lack of isoform transcomplementation in cardiac muscle. , 1998, Circulation research.

[37]  M. Fiszman,et al.  Cardiac myosin binding protein C gene is specifically expressed in heart during murine and human development. , 1998, Circulation research.

[38]  W. Rottbauer,et al.  Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. , 1997, The Journal of clinical investigation.

[39]  M. Komajda,et al.  Organization and sequence of human cardiac myosin binding protein C gene (MYBPC3) and identification of mutations predicted to produce truncated proteins in familial hypertrophic cardiomyopathy. , 1997, Circulation research.

[40]  J. Beckmann,et al.  Cardiac myosin binding protein–C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[41]  J. Seidman,et al.  Mutations in the cardiac myosin binding protein–C gene on chromosome 11 cause familial hypertrophic cardiomyopathy , 1995, Nature Genetics.

[42]  N. Alpert,et al.  Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro. , 1995, Circulation research.

[43]  J. Beckmann,et al.  Mapping of a novel gene for familial hypertrophic cardiomyopathy to chromosome 11 , 1993, Nature Genetics.

[44]  E. Lakatta,et al.  Cytosolic calcium and myofilaments in single rat cardiac myocytes achieve a dynamic equilibrium during twitch relaxation. , 1992, The Journal of physiology.

[45]  R. Moss,et al.  C‐protein limits shortening velocity of rabbit skeletal muscle fibres at low levels of Ca2+ activation. , 1991, The Journal of physiology.

[46]  H. C. Hartzell,et al.  Alterations in Ca2+ sensitive tension due to partial extraction of C- protein from rat skinned cardiac myocytes and rabbit skeletal muscle fibers , 1991, The Journal of general physiology.

[47]  A. Roulet,et al.  Specific programs of myosin expression in the postnatal development of rat muscles. , 1989, European journal of biochemistry.

[48]  D. Allen,et al.  The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle. , 1982, The Journal of physiology.

[49]  P. D. de Tombe.  Myosin binding protein C in the heart. , 2006, Circulation research.

[50]  H. Reichenspurner,et al.  The MLCK-mediated alpha1-adrenergic inotropic effect in atrial myocardium is negatively modulated by PKCepsilon signaling. , 2006, British journal of pharmacology.

[51]  E. Ostap.  2,3-Butanedione monoxime (BDM) as a myosin inhibitor , 2004, Journal of Muscle Research & Cell Motility.

[52]  M. Gautel,et al.  A molecular map of the interactions between titin and myosin-binding protein C. Implications for sarcomeric assembly in familial hypertrophic cardiomyopathy. , 1996, European journal of biochemistry.

[53]  B. Wolska,et al.  CGP-48506 increases contractility of ventricular myocytes and myofilaments by effects on actin-myosin reaction. , 1996, The American journal of physiology.